The Latest Breaking News from Cardinal Health

Cardinal Health is all set to announce its fourth-quarter results next month, and analysts are projecting double-digit earnings growth.

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

Cardinal Health’s shares have underperformed the broader market over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock.

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.87%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.02%. US stock indexes settled moderately higher on Monday, with the Dow Jones Industrials posting...

The S&P 500 rebounded Monday, led by Ford, United Airlines and megacap AI stock Nvidia. Verizon and Tesla were notable losers.

The S&P 500 Index ($SPX ) (SPY ) is up +1.33%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.53%. US stock indexes today are surging higher. Reduced geopolitical tensions are positive for stocks after...

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.04%. US stock indexes today are mixed. Reduced geopolitical tensions are positive for stocks...

A Relative Strength Rating upgrade for Cardinal Health shows improving technical performance. Will it continue?

Unlock the gates of wellness with these breakout healthcare stocks.

The medical sector is thriving, given the growing healthcare expenditure and rapid technological adoption. Given the industry’s tailwinds, fundamentally sound medical stocks Cardinal Health (CAH), Fresenius (FSNUY), and Zynex (ZYXI) could be ideal buys for substantial returns. Keep Reading….

Here's a look at three standout Dividend Aristocrats that not only offer stable income for yield hunters, but are delivering better returns than the broad market so far in 2023 - with more upside expected over the next year.